---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-24-000189"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:45:10.195964+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q2 revenue up 29% to $177.2M, raises FY2024 guidance; FDA approves Shield CRC test

## Summary
- Revenue $177.2M (+29% YoY); precision oncology revenue $166.5M (+33%).
- GAAP net loss $102.6M ($0.84/share); non-GAAP net loss $58.5M ($0.48 loss).
- FY2024 revenue guidance raised to $690-700M (prior $675-685M), growth 22-24%.
- Shield blood test received FDA approval for first-line CRC screening; commercial launch; Medicare covers 45M beneficiaries.
- Clinical tests 49,400 (+14%), biopharma tests 10,475 (+56%); cash $1.0B.

## SEC filing metadata
- accession: 0001576280-24-000189
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628024000189/0001576280-24-000189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628024000189/gh-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-24-000189
- JSON: https://secwatch.observer/filing/0001576280-24-000189.json
- Plain text: https://secwatch.observer/filing/0001576280-24-000189.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.